Heron Therapeutics Inc. (NASDAQ:HRTX) saw an upside of 1.81% to close Monday at $1.69 after adding $0.03 on the day. The 5-day average trading volume is 1,592,820 shares of the company’s common stock. It has gained $1.7850 in the past week and touched a new high 3 times within the past 5 days. An average of 2,043,150 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,009,832.
HRTX’s 1-month performance is 40.83% or $0.4900 on its low of $1.1900 reached on 07/10/23. The company’s shares have touched a 52-week low of $1.07 and high of $5.62, with the stock’s rally to the 52-week high happening on 01/18/23. YTD, HRTX has lost -32.40% or -$0.8100 and has reached a new high 7 times. However, the current price is down -69.93% from the 52-week high price.
Valuation Metrics
HRTX stock has a beta of 0.98. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.04.
Heron Therapeutics Inc.’s quick ratio for the period ended March 30 was 1.60, with the current ratio over the same period at 2.30. In terms of profitability, the gross margin trailing 12 months is 47.00%. The firm’s gross profit as reported stood at $52.8 million against revenue of $107.67 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Heron Therapeutics Inc.’s cash and short-term investments amounted to $32.93 million against total debt of $156.93 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -94.96% to -$32.77 million, while revenue of -$19.87 million was 39.37% off the previous quarter. Analysts expected HRTX to announce -$0.2 per share in earnings in its latest quarter, but it posted -$0.27, representing a -35.00% surprise. EBITDA for the quarter stood at more than -$32.77 million. HRTX stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 232.31 million, with total debt at $156.93 million. Shareholders hold equity totaling $119.72 million.
Let’s look briefly at Heron Therapeutics Inc. (HRTX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 07 August was 65.98% to suggest the stock is trending Neutral, with historical volatility in this time period at 77.15%.
The stock’s 5-day moving average is $1.6240, reflecting a +1.81% or $0.0300 change from its current price. HRTX is currently trading +30.00% above its 20-day SMA, -25.22% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +31.01% and SMA200 by-58.88%.
Stochastic %K and %D was 72.14% and 66.45% and the average true range (ATR) pointed at 0.1374. The RSI (14) points at 63.32%, while the 14-day stochastic is at 76.74% with the period’s ATR at 0.1342. The stock’s 9-day MACD Oscillator is pointing at 0.0422 and 0.0967 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Heron Therapeutics Inc. (NASDAQ: HRTX), Guggenheim launched coverage with a Buy rating. Analysts offering their rating for HRTX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate HRTX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 6 have offered a “buy” rating.
What is HRTX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $5.00 and a high of $10.00, with their median price target at $8.00. Looking at these predictions, the average price target given by analysts is for Heron Therapeutics Inc. (HRTX) stock is $7.75.
